James A. Mish
Chief Executive Officer
Mr. Mish was appointed Chief Executive Officer in June 2020. He has an outstanding track record of delivering profitable growth at both privately-held and publicly-traded science-driven companies with a focus on pharmaceutical and consumer products commercialization. Prior to joining 22nd Century, he served as President and Chief Executive Officer of Purisys, a synthetic cannabinoid API, ingredients and solutions provider to pharmaceutical and consumer products companies, and Noramco, a global leader in the production of controlled substances for the pharmaceutical industry. There, Mr. Mish led the private equity carve out of Noramco from Johnson & Johnson/Janssen Pharmaceuticals and spearheaded the subsequent creation and spinoff of Purisys from Noramco. Mr. Mish began his career at Pfizer in research and development before holding positions of increasing responsibility at several companies including as President of Ashland Specialty Ingredients - Consumer Specialties, a major division of Ashland Corporation, a premier, global specialty materials company serving customers in a wide range of consumer and industrial markets.
President & Chief Operating Officer
Mr. Zercher was appointed as our Company’s Chief Operating Officer in June 2019 and as our President in December 2019. From 2016 to 2019, Mr. Zercher served as our Company’s Vice President of Business Development. Prior to joining 22nd Century, Mr. Zercher headed Santa Fe Natural Tobacco Company’s international business operations based in Zurich, Switzerland, where he built a thriving international business with significant sales in twelve countries. Mr. Zercher has more than twenty years of experience in the tobacco industry in marketing, sales, operations and business development in the United States, Europe and Asia.
Chief Financial Officer
Mr. Franzino was appointed Chief Financial Officer in June 2020. He has a successful track record of strategic financial leadership in high-growth, highly regulated, consumer-facing industries as well as not-for-profit higher education organizations. Most recently, Mr. Franzino served as Chief Financial Officer of the West Point Association of Graduates, which supports the U.S. Military Academy at West Point. Prior to his experience in higher education, Mr. Franzino served as Chief Financial Officer of Santa Fe Natural Tobacco Company, a subsidiary of Reynolds American, Inc., and as Chief Financial Officer of Labatt USA, a subsidiary of Anheuser-Busch. In both roles, he was responsible for the financial planning and control function as well as information systems and technology. Mr. Franzino is a certified public accountant and holds a Master of Business Administration from Fairleigh Dickinson University and a Bachelor of Arts degree from the University of Maine at Farmington.
General Counsel and Corporate Secretary
Mr. Przybyla joined 22nd Century Group as General Counsel and Corporate Secretary in July 2020. Prior to joining 22nd Century, Mr. Przybyla served as President of the Medical Division at Jushi, Inc., a publicly traded, global cannabis and hemp company, where he led a variety of regulatory, legislative affairs, and strategic planning initiatives to advance Jushi’s medical cannabis and industrial hemp businesses. Mr. Przybyla also previously served as General Counsel for the Dent Neurologic Group, LLP and Seneca Development Corporation. He holds a Juris Doctor from Columbia Law School where he was a Harlan Fiske Stone Scholar, and a Bachelor of Arts in Economics from Washington and Lee University.
Juan Sanchez Tamburrino
Ph.D., MBA, Vice President of Research and Development
Dr. Tamburrino was appointed Vice President of Research and Development in December 2017. Following six years of post-doctoral research at the Rockefeller University in New York, Dr. Tamburrino served as an Associate Professor at Universidad Tarapacá in Chile before becoming the Research Manager at Pioneer Hi-Bred International (now known as DuPont Pioneer). In 2009, Dr. Tamburrino was appointed the head of the Plant Biotechnology Division of British American Tobacco in Cambridge, England, where he was responsible for biotechnology strategy related to tobacco leaf. Dr. Tamburrino holds a Ph.D. degree in molecular biology and genetics from the Weill Cornell Graduate School of Medical Sciences at Cornell University, a partnership program with the Sloan Kettering Cancer Research Institute, and he is a Master of Business Administration candidate at the University of Bradford in Bradford, U.K.
John T. Brodfuehrer
Interim Director of Human Resources
Mr. Brodfuehrer was appointed as our Vice President of Strategy in December 2019 after having served as our Chief Financial Officer from March 2013 to December 2019. From March 2011 to December 2012, Mr. Brodfuehrer served as the Chief Financial Officer of Latina Boulevard Foods, LLC, or LBF, an entity formed as the result of a merger of two long-time Western New York wholesale food distributors. Prior to his employment with LBF, Mr. Brodfuehrer was Vice-President of Retail Accounting for United Refining Company, or URC. Prior to his time at URC, Mr. Brodfuehrer served in multiple roles over a twenty-four year span with NOCO Energy Corp, a diversified distributor of energy products and related services. Mr. Brodfuehrer served as NOCO’s Chief Financial Officer, Vice-President and as a member of the Board of Directors from 2000 to 2009. Mr. Brodfuehrer earned a Bachelor of Science in Business Administration, summa cum laude, from the State University of New York at Buffalo in 1979 and became a New York State Certified Public Accountant in 1981.
John D. Pritchard
Vice President of Regulatory Science
Mr. Pritchard joined 22nd Century Group as our Vice President of Regulatory Science in April 2019. Prior to that time, Mr. Pritchard was the Head of Regulatory Science for Imperial Brands, where he led that company’s technical regulatory strategy and external scientific engagement on global product regulation. Before joining Imperial Brands, Mr. Pritchard was a Toxicologist with both the U.K. Health Protection Agency (now, Public Health England) and Charles River, a leading global contract research organization for the pharmaceutical industry. Mr. Pritchard received a Master of Science Degree in Toxicology from the University of Birmingham, England and his Bachelor of Science Degree with honors in Pharmacology from the University of Aberdeen, Scotland.